CAMBRIDGE, Mass., June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and well-being in historically undersupported communities. The initiative is part of Sanofi's broader commitment to improve equitable access to healthcare by addressing structural factors, such as lack of access to housing, food, and behavioral health.
Launched earlier this year, the Fund strategically invests in nonprofit partners with deep roots in the communities they serve. Selected from Sanofi's existing network of Massachusetts-based partners, the grantees will use the funding over the next year to scale programs that address root causes of health disparities while delivering measurable impact for historically undersupported populations.
Deborah Glasser
Head, Specialty Care North America and US Country Lead, Sanofi
"Sanofi believes that the most sustainable health solutions are created by and for the communities closest to the challenges. Through the Healthy Futures Solution Fund, we are honored to support local organizations that possess deep knowledge, lived experience, and trusted relationships at the community level. By investing in their work, we're helping to accelerate progress toward stronger and more equitable health outcomes for all."
The inaugural grantees of the Healthy Futures Solution Fund are:
Stan McLaren, MBA
Chief Executive Officer, Boston Health Care for the Homeless Program
"This funding is an investment in the dignity and well-being of the people we serve. With Sanofi's support, we're able to expand access to integrated care for individuals experiencing homelessness — meeting them where they are and helping address both medical needs and social factors that impact their health."
The funding period runs through June 2026. At the end of the program, each organization plans to submit an impact report outlining measurable outcomes, learnings, and stories about how the grant affected their community.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Evan Berland | +1 215 432 0234 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Léo Le Bourhis | + 33 6 75 06 43 81 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Victor Rouault | + 33 6 70 93 71 40 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Timothy Gilbert | + 1 516 521 2929 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Léa Ubaldi | +33 6 30 19 66 46 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
Thomas Kudsk Larsen | + 44 7545 513 693 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Alizé Kaisserian | + 33 6 47 04 12 11 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Felix Lauscher | + 1 908 612 7239 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Keita Browne | + 1 781 249 1766 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Nathalie Pham | + 33 7 85 93 30 17 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Tarik Elgoutni | + 1 617 710 3587 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Thibaud Châtelet | + 33 6 80 80 89 90 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Yun Li | +33 6 84 00 90 72 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$49.34 |
Daily Change: | 0.51 1.04 |
Daily Volume: | 1,987,367 |
Market Cap: | US$120.390B |
October 16, 2024 September 16, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load